Press Releases

Hero overlay Cancer research Analyst Coverage Annual Report Proxy Materials Corporate Governance Events Presentations Financial Information Investor Disclaimer Press Releases Stock Information
MENLO PARK, Calif. , Aug. 3, 2022 /PRNewswire/ -- PacBio (NASDAQ: PACB) today announced financial results for the quarter ended June 30, 2022 .     Second quarter results Revenue of $35.5 million , a 16% increase compared with $30.6 million in the prior year period.
August 3, 2022
MENLO PARK, Calif., June 27, 2022 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading provider of high-quality, highly accurate sequencing platforms, today announced that the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options covering an aggregate of
June 27, 2022
MENLO PARK, Calif., May 04, 2022 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced financial results for the quarter ended March 31, 2022. First quarter results Revenue of $33.2 million, a 14% increase compared with $29.0 million in the prior year period.
May 4, 2022
Significant enhancements to the Sequel II/IIe platform include methylation calling in native DNA, greatly accelerated sample preparation, and support for gene therapy applications MENLO PARK, Calif., April 21, 2022 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality,
April 21, 2022

Investor Contact

Pacific Biosciences of California, Inc.
1305 O’Brien Drive, Menlo Park, CA 94025
ir@pacb.com